Cargando…

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis

OBJECTIVE: Candida species are responsible for fungal diseases and the development of nosocomial bloodstream infections. Treatment is resource-intensive and economically challenging for healthcare systems. Cost analyses of drugs against candidiasis, such as rezafungin, are thus of great interest to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeck, Julia, Jakobs, Florian, Kurte, Melina S, Cornely, Oliver A, Kron, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279419/ https://www.ncbi.nlm.nih.gov/pubmed/37342199 http://dx.doi.org/10.1093/jacamr/dlad079

Ejemplares similares

A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital
por: Jeck, Julia, et al.
Publicado: (2021)

Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany
por: Jeck, Julia, et al.
Publicado: (2022)

A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
por: Jakobs, Florian, et al.
Publicado: (2021)

Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier
por: Jakobs, Florian, et al.
Publicado: (2022)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Cost Comparison of Treatment Alternatives for Pleural Effusion and Ascites from a Payer Perspective: Are There Cost Savings from Indwelling Catheters?
por: Siefen, Ann-Cathrine, et al.
Publicado: (2023)

S313: HEALTH ECONOMIC EVALUATION OF THIRD-LINE INTERVENTIONS FOR TRANSPLANT-INELIGIBLE RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GERMANY
por: Sophie Kurte, Melina, et al.
Publicado: (2023)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

Health Economic Aspects of Platelet Concentrates: Comparing Cost and Reimbursement of Pathogen Inactivated and Conventional Platelet Concentrates in a German Comprehensive Cancer Center
por: Bonn, Jennifer, et al.
Publicado: (2023)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

The evaluation of cost-of-illness due to use of cost-of-illness-based chemicals
por: Hong, Jiyeon, et al.
Publicado: (2015)

Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort
por: Stoll, Matthias, et al.
Publicado: (2011)

Minimally important difference in cost savings: Is it possible to identify an MID for cost savings?
por: Dooley, Mary, et al.
Publicado: (2021)

Lymphedema self-care: economic cost savings and opportunities to improve adherence
por: Karaca-Mandic, Pinar, et al.
Publicado: (2023)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital
por: Frings, Verena Gerlinde, et al.
Publicado: (2021)

Cost-of-illness of knee osteoarthritis: potential cost savings by not undergoing arthroplasty within the first 2 years
por: Ong, Kevin L, et al.
Publicado: (2019)

Canadian Potential Healthcare and Societal Cost Savings from Consumption of Pulses: A Cost-Of-Illness Analysis
por: Abdullah, Mohammad M. H., et al.
Publicado: (2017)

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
por: Soriano, A, et al.
Publicado: (2023)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

Economic costs of obesity in Thailand: a retrospective cost-of-illness study
por: Pitayatienanan, Paiboon, et al.
Publicado: (2014)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

Prevention is life- and cost-saving
por: Baussano, Iacopo, et al.
Publicado: (2020)

The costs of the economic crisis in the health sector
por: Radu, Paul, et al.
Publicado: (2009)

Correction: Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital
por: Frings, Verena Gerlinde, et al.
Publicado: (2021)

The economic costs of illness: A replication and update
por: Rice, Dorothy P., et al.
Publicado: (1985)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

Economic Modeling of Heart Failure Telehealth Programs: When Do They Become Cost Saving?
por: Liu, Sheena Xin, et al.
Publicado: (2016)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
por: Nenadić, Ilija, et al.
Publicado: (2017)

The HEART Pathway and Hospital Cost Savings
por: Yau, Amy A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jaqgtdch2t0g94a99dvmfigt3r